Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV disease ...
CMV is the most common infectious cause of birth defects in the U.S.; there is no approved vaccine to prevent CMV CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage ...
CMV screening and valacyclovir use increased after a landmark French trial. Find out how practice patterns changed in ...
Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results